Blog
-
NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman
NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske and Stefan Duhr have redefined their roles to better position the company for continued growt
-
NanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market
NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...
-
NanoTemper Technologies Establishes Advisory Board to Propel Innovation and Growth
NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...
-
5 considerations for buffer optimization during biologics pre-formulation
The work of pre-formulations scientists is critical to de-risk the entire development process for biologics. Read on to learn more about what to consider about your buffer components for...
-
5 types of formulation excipients and how they impact biologics stability
Each excipient class helps stabilize biologics – from monoclonal antibodies to vaccine antigens – in different ways. Read on to learn more about some of the most important excipients for...
-
NanoTemper brings Spectral Shift technology to the protein production market with Andromeda X, enabling biopharma and CROs
NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein...
-
Three things we took away from attending Drug Discovery Chemistry in 2024
Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...
-
Get predictive insight into your ADC’s stability with these 3 experiments
Learn how it’s possible to use the Prometheus Panta to extrapolate how your low concentration sample will behave once it’s scaled up and at higher concentrations used for clinical administration.
-
5 biologics conferences you won’t want to miss in 2024
Use this list of crowd-sourced favorites to kick-start your 2024 biologics conference plans. Find out when and where each conference takes place, who will be there, which topics are covered, and...
- Contact Specialist
-
Attend these targeted protein degradation conferences in 2024 to stay in the know
Attending dedicated targeted protein degradation conferences and tracks is a great way to keep up with this rapidly evolving field. Here are 8 conferences you’ll want to attend in 2024.
-
De-risk your ADC development process with these stability considerations
Antibody-drug conjugates, or ADCs, are revolutionary therapeutics that represent a growing proportion of the biologics market. They combine the targeting power of a monoclonal antibody, which is...
-
How stability characterization parameters help you create biologics developability profiles
Developability profiles help you avoid risk by collecting many quality attributes associated with each candidate, enabling you to rank each candidate by the most optimal attributes and make a...
-
How to predict your biologics candidates' behavior at high concentrations with light-scattering techniques
Light scattering techniques are used to predict high-concentration behavior of candidates early in the development process. Let's take a look at what they tell you, how to set them up, and how...
-
What to consider when adding DLS to your early biologics development workflow
Read on to find the answers to questions your early development scientist peers have asked about how to use DLS to design, select, and advance the most stable biologics candidates.
-
How early discovery and development teams use DLS to de-risk downstream biologics development
As a discovery or early development scientist, you’re tasked with identifying the most promising biologics candidates. Your hard work during early development enables straightforward and efficient...
-
8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...
-
8 biologics conferences you won’t want to miss in 2023
When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeutics approvals, and big pharma news, but nothing matches the biologics conference experience.
-
NanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail
NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
-
5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
-
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
- Loading more...